WOUNDCHEK™ Protease Status Point of Care (POC) Diagnostic Test on DFU

Inclusion Criteria: * Men and women aged ≥ 18 years old * Patients with a diabetic foot ulcer as defined by Wagner grade 1 - 2 * ABPI of ≥0.6 to ensure ischemia will not impact healing * No restriction on wound size or wound location * Duration of ulcer ≥ 6 weeks ≤ 2 years * The patient must be able to understand the trial and provide written informed consent * No local or systemic signs of infection, with normal CRP and leukocyte levels below 10 000 * Wound has not been treated with PROMOGRAN® in 4 weeks prior to inclusion Exclusion Criteria: * Wound duration of less than 6 weeks or longer than 2 years * Known hypersensitivity to any of the wound dressing used in the trial * Current local or systemic antibiotics in the week prior to inclusion * Patients with significant ischemia as defined by ABPI of ≤0.6 * Clinical infected wound as determined by the presence of 3 or more of the following clinical signs: perilesional erythema, pain between two dressing changes, malodorous wound, abundant exudate and oedema. * Progressive neoplastic lesion treated by radiotherapy or chemotherapy * Prolonged treatment with immunosuppressive agents or high dose corticosteroids * Patients who have a current illness or condition which may interfere with wound healing in the last 30 days (carcinoma, connective tissue disease, autoimmune disease or alcohol or drug abuse) * Patients with renal insufficiency (with eGFR values \<30 or on RRT) Life expectancy of \<6 months * Patients with uncontrolled diabetes as determined by Hb-A1c ≥ 12% ( = Hb-1CIFCC ≥ 107.65 mmol/mol) * Patients who have participated in a clinical trial on wound healing within the past month * Patients who are unable to understand the aims and objectives of the trial * Patients with a known history of non adherence with medical treatment * Females who are pregnant * Subject has Acquired Immunodeficiency Syndrome (AIDS) or is known to be infected with Human Immunodeficiency Virus (HIV) * Subject has viral hepatitis